Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of UC-MSC Therapy for Spinocerebellar Ataxia
NCT03378414Phase 2Not yet recruiting
- Sponsor
- Sclnow Biotechnology Co., Ltd.
- Start
- Dec 2026
- Primary completion
- Jun 2027
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, randomised, open-label trial of human umbilical cord mesenchymal stem cells in spinocerebellar ataxia (SCA) (3 arms), sponsored by Sclnow Biotechnology Co., Ltd. Primary endpoint: Scale for the Assessment and Rating of Ataxia at 12 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
spinocerebellar ataxia (SCA)
Beyond the preview
Go deeper on NCT03378414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03378414.